# JDQ443

Source: https://onco.cc/drugs/jdq443/  
OnCo record `jdq443` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

JDQ443 is an experimental small-molecule drug from Novartis Pharmaceuticals in phase 3 trials for non-small-cell lung cancer and colorectal cancer, aimed at KRAS.

## Summary

JDQ443 is a small-molecule drug developed by Novartis Pharmaceuticals. Its target is KRAS (the sponsor names KRAS G12C). ClinicalTrials.gov describes the intervention as: JDQ443 per os (PO) 200 mg twice a day continuously. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT05132075 (Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer), in non-small-cell lung cancer and colorectal cancer. The largest, NCT04699188, plans to enrol 344 participants (actual) with primary completion expected 2027-01-25. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: small molecule
- Mechanism: Small-molecule drug directed at KRAS, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of JDQ443: https://clinicaltrials.gov/search?intr=JDQ443

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [KRAS](https://onco.cc/targets/kras/)
- companies: [Novartis](https://onco.cc/companies/novartis/)
- trials: [Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation](https://onco.cc/trials/nct05358249/), [Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other](https://onco.cc/trials/nct07468071/), [Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.](https://onco.cc/trials/nct05445843/), [Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer](https://onco.cc/trials/nct05132075/), [Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation](https://onco.cc/trials/nct04699188/)

---
JSON: https://onco.cc/api/v1/entities/jdq443.json